Compare ATI & VTRS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | ATI | VTRS |
|---|---|---|
| Founded | 1960 | 1961 |
| Country | United States | United States |
| Employees | 7600 | 30000 |
| Industry | Steel/Iron Ore | Medicinal Chemicals and Botanical Products |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 21.6B | 17.7B |
| IPO Year | 1996 | 2019 |
| Metric | ATI | VTRS |
|---|---|---|
| Price | $153.45 | $16.54 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 8 | 4 |
| Target Price | ★ $153.75 | $13.50 |
| AVG Volume (30 Days) | 1.7M | ★ 12.1M |
| Earning Date | 04-30-2026 | 05-07-2026 |
| Dividend Yield | N/A | ★ 3.21% |
| EPS Growth | ★ 11.76 | N/A |
| EPS | ★ 0.85 | 0.15 |
| Revenue | $4,043,500,000.00 | ★ $14,299,900,000.00 |
| Revenue This Year | $9.52 | $4.41 |
| Revenue Next Year | $9.02 | $1.96 |
| P/E Ratio | $176.36 | ★ $107.30 |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $70.42 | $8.19 |
| 52 Week High | $171.11 | $17.53 |
| Indicator | ATI | VTRS |
|---|---|---|
| Relative Strength Index (RSI) | 47.10 | 61.48 |
| Support Level | $139.22 | $9.82 |
| Resistance Level | $167.10 | N/A |
| Average True Range (ATR) | 6.33 | 0.59 |
| MACD | -1.11 | -0.04 |
| Stochastic Oscillator | 27.47 | 64.61 |
ATI Inc supplies specialty metals to various end markets, including aerospace and defense, oil and gas, automotive, and electrical energy, among many others. The company's operating segment includes High-Performance Materials and Components and Advanced Alloys and Solutions. The majority of revenue is from the High-Performance Materials segment. The High-Performance Materials segment is focused on a wide range of high-performance specialty materials, parts, and components for several the majority of end markets, including the aerospace & defense, medical, and energy markets. Geographically, it operates in the United States, China, the United Kingdom, Germany, France, Canada, and Others, the majority is from the United States.
Viatris was formed in November 2020 through the combination of Upjohn, a wholly owned subsidiary of Pfizer that specialized in off-patent drugs, and Mylan, a global pharmaceutical manufacturer that focused on generic and specialty drugs. By joining forces, Viatris became one of the largest generic drug manufacturers in the world, servicing over 165 countries. Generics (commoditized and complex) and biosimilars make up roughly 40% of Viatris' total sales. The remaining 60% of sales are derived from its portfolio of legacy products, which includes Lipitor, Norvasc, Lyrica, and Viagra. While it covers more than 10 major therapeutic areas, Viatris has identified dermatology, ophthalmology, and gastroenterology as its three key areas of focus for future innovations.